44 results on '"Larché, M"'
Search Results
2. POS0111 MORE METICULOUSLY FOLLOWING TREAT-TO-TARGET IN RA DOES NOT LEAD TO LESS RADIOGRAPHIC PROGRESSION: A LONGITUDINAL ANALYSIS IN BIODAM
3. Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis
4. Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis
5. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia
6. Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype
7. OP0192 Adding ultrasound to the treat-to-target strategy shows no benefit in achievement of remission: results from the biodam cohort
8. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper
9. Novel approaches and perspectives in allergen immunotherapy
10. The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study
11. Treatment with anti‐cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity
12. T regulatory cell phenotypes in peripheral blood and bronchoalveolar lavage from non‐asthmatic and asthmatic subjects
13. Fel d 1‐derived synthetic peptide immuno‐regulatory epitopes show a long‐term treatment effect in cat allergic subjects
14. Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy
15. T cell-mediated induction of thymic stromal lymphopoietin in differentiated human primary bronchial epithelial cells
16. OX 40L blockade and allergen‐induced airway responses in subjects with mild asthma
17. Cytokine responses of peripheral blood mononuclear cells to allergen do not identify asthma or asthma phenotypes
18. Validation of Peptide Immunotherapy as a New Approach in the Treatment of Allergic Rhinoconjunctivitis: The Clinical Benefits of Treatment with Amb a 1 Derived T cell Epitopes
19. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy
20. Immunotherapy with peptides
21. Development and Preliminary Clinical Evaluation of a Peptide Immunotherapy Vaccine for Cat Allergy
22. Induction of Thymic Stromal Lymphopoietin (TSLP) in Airway Epithelium by Recombinant Allergens
23. Of cats and men: immunodominance and the role of HLA-DP/DQ
24. Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics
25. Indirect Recognition of T-Cell Epitopes Derived from the α3 and Transmembrane Domain of HLA-A2
26. Peptide immunotherapy for allergic diseases
27. Induction of interleukin‐10 and suppressor of cytokine signalling‐3 gene expression following peptide immunotherapy
28. Recruitment of CD4 cells during peptide-induced isolated late asthmatic reactions is associated with increased TARC expression
29. Treatment of bee venom allergic subjects with phospholipase A2 T Cell epitope peptides results in iincreased expression of mRNA encoding suppressor of cytokine signalling (SOCS) 3 and a transient increase in allergen-specific IgG/G4
30. Fel d 1‐derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon‐γ+ T helper type 1 cells to sites of allergen‐induced late‐phase skin reactions in cat‐allergic subjects
31. Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double‐blind placebo‐controlled study
32. Late asthmatic reactions provoked by intradermal, but not inhaled, allergen-derived T-cell peptides induce “Tolerance” to subsequent antigen challenge
33. Anti‐T‐cell strategies in the treatment of allergic disease
34. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial
35. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma
36. Allergen isoforms for immunotherapy: diversity, degeneracy and promiscuity
37. T‐cell responses to house dust mites: bad news for immunotherapy?
38. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics.
39. EnhancedIn VivoImmunogenicity Induced by an Antibody to the IL-4 Receptor-Associated gp200-MR6 Molecule
40. FcεRI expression on monocytes in atopic disease: cause or effect?
41. A single strand conformation polymorphism study of CD40 ligand. Efficient mutation analysis and carrier detection for X-linked hyper IgM syndrome.
42. Hyper IgM syndrome associated with defective CD40-mediated B cell activation.
43. Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?
44. T and B cell ontogeny and phylogeny
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.